Edition:
United States

ESSA Pharma Inc (EPIX.OQ)

EPIX.OQ on NASDAQ Stock Exchange Capital Market

0.22USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
31,543
52-wk High
$3.59
52-wk Low
$0.21

Latest Key Developments (Source: Significant Developments)

Essa Pharma Announces Pricing Of Previously Announced Equity Offering
Wednesday, 13 Dec 2017 08:55am EST 

Dec 13 (Reuters) - Essa Pharma Inc ::ESSA PHARMA ANNOUNCES PRICING OF PREVIOUSLY ANNOUNCED EQUITY OFFERING.ESSA PHARMA INC - ‍ESSA INTENDS TO ISSUE COMMON SHARES IN CAPITAL OF COMPANY AT A PRICE OF US$0.20 PER COMMON SHARE.  Full Article

ESSA Pharma announces overnight marketed equity offering
Tuesday, 12 Dec 2017 05:23pm EST 

Dec 12 (Reuters) - Essa Pharma Inc ::ESSA PHARMA ANNOUNCES OVERNIGHT MARKETED EQUITY OFFERING.ESSA PHARMA - TO USE NET PROCEEDS OF OFFERING PRIMARILY TO CONTINUE ONGOING PRECLINICAL DEVELOPMENT OF CO'S ANITEN COMPOUNDS.  Full Article

Essa Pharma Reports Qtrly Loss Per Share Of $0.07
Monday, 11 Dec 2017 09:21pm EST 

Dec 11 (Reuters) - ESSA Pharma Inc ::ESSA PHARMA ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FOURTH QUARTER AND YEAR ENDED SEPTEMBER 30, 2017.QTRLY BASIC AND DILUTED LOSS PER COMMON SHARE $0.07‍​.‍CASH ON HAND AS AT SEPTEMBER 30, 2017 WAS $3.98 MILLION, WITH WORKING CAPITAL OF $1.28 MILLION​.  Full Article

Essa Pharma announces results from the phase 1 clinical trial of EPI-506
Monday, 11 Sep 2017 07:31am EDT 

Sept 11 (Reuters) - Essa Pharma Inc :Essa Pharma announces results from the phase 1 clinical trial of epi-506 for treatment of MCRPC and updates clinical and strategic plans.Confirmed EPI-506 is well-tolerated with a favorable safety profile​.Essa initiates corporate restructuring to refocus research and development efforts​.Makes strategic decision to prioritize Aniten program for MCRPC over further clinical development of epi-506​.Corporate restructuring associated with updated clinical plan expected to lower capex in fiscal 2018 by about $7 million versus fiscal 2017.Anticipates that its current resources are sufficient to support planned operations into fourth calendar quarter of 2017​.Essa will discontinue further clinical development of EPI-506.Will implement a corporate restructuring plan to focus research and development resources on its next-generation Anitens targeting AR-NTD​.  Full Article

ESSA Pharma qtrly loss per share $0.12
Monday, 14 Aug 2017 09:25pm EDT 

Aug 14 (Reuters) - Essa Pharma Inc :ESSA Pharma provides business update and announces financial results for the fiscal third quarter ended June 30, 2017.Qtrly loss per share $0.12.  Full Article

ESSA Pharma provides further update on proposed equity offering
Monday, 24 Jul 2017 07:30am EDT 

July 24 (Reuters) - Essa Pharma Inc :Says additional data is currently being received from higher dose cohorts in Phase 1 clinical trial of EPI-506.Says intends to delay an offering until after that data can be announced from ongoing highest dose cohorts.Says it will provide further updates as they become available.  Full Article

Essa Pharma announces update to proposed equity offering
Tuesday, 18 Jul 2017 08:04am EDT 

July 18 (Reuters) - Essa Pharma Inc ::Essa Pharma announces update to proposed equity offering.Essa Pharma-financial regulators informed concentration of proposed insider participation exceeded permitted levels, conditional approval was denied ​.Essa Pharma Inc says company will not proceed with proposed offering but may consider alternative acceptable transaction structures.  Full Article

ESSA Pharma says intends to issue units of co at US$0.44/unit
Thursday, 13 Jul 2017 11:57am EDT 

July 13 (Reuters) - ESSA Pharma Inc ::ESSA Pharma announces pricing of proposed equity offering.Says ESSA intends to issue units of company at a price of US$0.44 per unit.Each unit will be comprised of one common share of company and one common share purchase warrant.Each warrant will be exercisable at a price of US$0.51, entitle holder thereof to acquire 1 common share of co for a period 5 years.  Full Article

Essa Pharma announces overnight marketed equity offering
Wednesday, 12 Jul 2017 04:10pm EDT 

July 12 (Reuters) - Essa Pharma Inc ::Essa Pharma announces overnight marketed equity offering.Essa Pharma Inc - proceeds of offering will be used for company's pre-clinical and clinical development of prostate cancer programs.  Full Article

Essa Pharma reports Q2 loss per share $0.26
Monday, 15 May 2017 07:30am EDT 

May 15 (Reuters) - Essa Pharma Inc :Essa Pharma provides business update and announces financial results for the second quarter ended March 31, 2017.Q2 loss per share $0.26.  Full Article